Granted Patent
B1
US 12,559,752 · App. 19/092,703 · Granted Feb 24, 2026
Composition for regulating production of interfering ribonucleic acid
Assignee:
Wyvern Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a cytokine or other mediator molecule of an inflammatory response.
Claims (2)
1 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is identical to SEQ ID NO: 18, wherein the sequence of nucleotides that is identical to SEQ ID NO: 18 comprises an insert sequence of nucleotides that is identical to SEQ ID NO: 8.
2 . The composition of claim 1 , wherein the RP is encapsulated in a protein coat, a lipid vesicle, or any combination thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 21, 2025
From: THOMPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 072083/0016 →
Continuity (1)
References Cited (57)
CA 2721333A1
· 2009
[cited by applicant]
CN 108998451A
· 2018
[cited by applicant]
O' Brien at al., “Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation”, Frontiers in Endocrinology, vol. 9, Published Aug. 3, 2018. (Year: 2018).
[cited by examiner]
Zhang et al., “The Risks of miRNA Therapeutics: In a Drug Target Perspective”, Drug Design, Development and Therapy, Published Feb. 22, 2021, pp. 721-733. (Year: 2021).
[cited by examiner]
Gorski et al., “RNA-based recognition and targeting: sowing the seeds of specificity”, Nat Rev Mol Cell Biol 18, 215-228, 2017. (Year: 2017).
[cited by examiner]
Denzler et al., “Impact of MicroRNA Levels, Target-Site Complementarity, and Cooperativity on Competing Endogenous RNA-Regulated Gene Expression”, Mol Cell. Nov. 3, 2016;64(3):565-579. (Year: 2016).
[cited by examiner]
Van den Berg, et al., “Design of Effective Primary MicroRNA Mimics With Different Basal Stem Conformations”, pp. 1-12, Molecular Therapy, Nucleic Acids, vol. 5, 2016. (Year: 2016).
[cited by examiner]
Zhang et al. “Cytokines, inflammation, and pain.” International anesthesiology dimes 45.2 (2007): 27-37.
[cited by applicant]
Asirvatham et al. “miRNA regulation of cytokine genes.” Cytokine 45.2 (2009): 58-69.
[cited by applicant]
GenBank IL-1b mRNA Sequence (2023).
[cited by applicant]
Nature (2010. Gene Expression. Scitable. Available online at Nature.com) <https://www.nature.com/scitable/topicpage/gene-expression-14121669> (2010).
[cited by applicant]
Tritschler et al. “Concepts and limitations for learning developmental trajectories from single cell genomics.” Development 146.12 (2019): dev170506.
[cited by applicant]
GenBank IL-1b gene Sequence (2023).
[cited by applicant]
GenBank IL-18 mRNA Sequence (2023).
[cited by applicant]
Shang et al. “microRNAs in action: biogenesis, function and regulation.” Nature Reviews Genetics 24.12 (2023): 816-833.
[cited by applicant]
Depieri et al. “RNAi mediated IL-6 in vitro knockdown in psoriasis skin model with topical siRNA delivery system based on liquid crystalline phase.” European Journal of Pharmaceutics and Biopharmaceutics 105 (2016): 50-…
[cited by applicant]
Yuan et al. “Interleukin-6 RNA knockdown ameliorates acute lung injury induced by intestinal ischemia reperfusion in rats by upregulating interleukin-10 expression.” Molecular Medicine Reports 16.3 (2017): 2529-2537.
[cited by applicant]
Teoh et al. “Small interfering RNA silencing of interleukin-6 in mesenchymal stromal cells inhibits multiple myeloma cell growth.” Leukemia Research 40 (2016): 44-53.
[cited by applicant]
[cited by applicant]
[cited by applicant]
[cited by applicant]
Agarwal et al. “Predicting effective microRNA target sites in mammalian mRNAs.” elife 4 (2015): e05005.
[cited by applicant]
Fayyad-Kazan et al. “Downregulation of microRNA-24 and-181 parallels the upregulation of IFN-γ secreted by activated human CD4 lymphocytes.” Human immunology 75.7 (2014): 677-685.
[cited by applicant]
[cited by applicant]
[cited by applicant]
[cited by applicant]
[cited by applicant]
Li et al. “miR-190a-5p partially represses the abnormal electrical activity of SCN3B in cardiac arrhythmias by downregulation of IL-2.” Frontiers in Cardiovascular Medicine 8 (2022): 795675.
[cited by applicant]
Xu et al. “MicroRNA-26a-mediated regulation of interleukin-2 expression in transformed avian lymphocyte lines.” Cancer cell international 10 (2010): 1-7.
[cited by applicant]
[cited by applicant]
Lam et al. “siRNA versus miRNA as therapeutics for gene silencing.” Molecular therapy Nucleic acids 4 (2015).
[cited by applicant]
Ying et al. “The microRNA (miRNA): overview of the RNA genes that modulate gene function.” Molecular biotechnology 38 (2008): 257-268.
[cited by applicant]
Bottoni et al. “Targeting BTK through microRNA in chronic lymphocytic leukemia.” Blood, The Journal of the American Society of Hematology 128.26 (2016): 3101-3112.
[cited by applicant]
Brutons Tyrosine Kinase Genbank Sequence (2023).
[cited by applicant]
Christensen et al., “Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo.” Frontiers in neural circuits 3 (2010): 848.
[cited by applicant]
Bofill-De Ros et al. “Guidelines for the optimal design of miRNA-based shRNAs.” Methods 103 (2016): 157-166.
[cited by applicant]
Gen Bank EGF Sequence (2023).
[cited by applicant]
Ahmadzadeh et al. “BRAF mutation in hairy cell leukemia.” Oncology reviews 8.2 (2014): 253.
[cited by applicant]
Patton et al. “Biogenesis, delivery, and function of extracellular RNA.” Journal of extracellular vesicles 4.1 (2015): 27494.
[cited by applicant]
Clark et al. “Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies,” Oncotarget 11.44 (2020): 4016.
[cited by applicant]
NCBI Search results for SEQ ID No. 5 2024.
[cited by applicant]
NCBI Nucleotide Sequence ALK Lingand, search performed Dec. 26, 2024 (2023).
[cited by applicant]
NCBI Nucleotide Sequence ALK Receptor, search performed Dec. 26, 2024 (2023).
[cited by applicant]
GenBank EGFR Sequence (2023).
[cited by applicant]
Genbank FLT3 Sequence (2024).
[cited by applicant]
NCBI Nucleotide Sequence for PARP, search performed Dec. 26, 2024 (2024).
[cited by applicant]
Kondratov et al. “Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells.” Molecular Therapy 25.12 (2017): 2661-2675.
[cited by applicant]
Wang et al. “Adeno-associated virus vector as a platform for gene therapy delivery”. Nat Rev Drug Discov. May 2019; 18(5):358-378. (Year: 2019).
[cited by applicant]
Momin et al., 2021, Cells, 10, 3097, p. 1-21 (Year: 2021).
[cited by applicant]